- Home
- TXO vs MBX Comparison
TXO vs MBX Comparison
Compare TXO & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- MBX
- Stock Information
- Founded
- TXO 2012
- MBX 36
- Country
- TXO United States
- MBX United States
- Employees
- TXO N/A
- MBX N/A
- Industry
- TXO Oil & Gas Production
- MBX
- Sector
- TXO Energy
- MBX
- Exchange
- TXO Nasdaq
- MBX NYSE
- Market Cap
- TXO 692.7M
- MBX 644.6M
- IPO Year
- TXO 2023
- MBX 2024
- Fundamental
- Price
- TXO $19.35
- MBX $10.23
- Analyst Decision
- TXO Strong Buy
- MBX Strong Buy
- Analyst Count
- TXO 2
- MBX 4
- Target Price
- TXO $26.00
- MBX $37.25
- AVG Volume (30 Days)
- TXO 116.0K
- MBX 360.9K
- Earning Date
- TXO 03-04-2025
- MBX 02-16-2025
- Dividend Yield
- TXO 12.29%
- MBX N/A
- EPS Growth
- TXO N/A
- MBX N/A
- EPS
- TXO N/A
- MBX N/A
- Revenue
- TXO $285,451,000.00
- MBX N/A
- Revenue This Year
- TXO N/A
- MBX N/A
- Revenue Next Year
- TXO $28.33
- MBX N/A
- P/E Ratio
- TXO N/A
- MBX N/A
- Revenue Growth
- TXO N/A
- MBX N/A
- 52 Week Low
- TXO $15.22
- MBX $9.42
- 52 Week High
- TXO $23.56
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- TXO 75.83
- MBX N/A
- Support Level
- TXO $16.49
- MBX N/A
- Resistance Level
- TXO $19.50
- MBX N/A
- Average True Range (ATR)
- TXO 0.67
- MBX 0.00
- MACD
- TXO 0.32
- MBX 0.00
- Stochastic Oscillator
- TXO 95.02
- MBX 0.00
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.